Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naxitamab in Newly Diagnosed High-Risk Neuroblastoma
NCT05489887Phase 2Recruiting
- Start
- Sep 2022
- Primary completion
- Sep 2029
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of naxitamab in neuroblastoma. Primary endpoint: Complete Response rate per 1993 INRC guidelines. Started Sep 2022; status: recruiting.
02
Drugs
naxitamab
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT05489887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05489887.